Oral Iron Therapy in Chronic Heart Failure Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-08-31

Study Completion Date

2016-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is design to evaluate the effectiveness of oral iron therapy in patients with heart failure and identify the central and peripheral mechanisms involved in the improvement of functional capacity after intervention. The investigation includes subjective and objective measures on exercise performance and heart function after intervention, and the tolerability of oral iron treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Iron Supplementation in Heart Failure Patients With Anemia: The IRON-HF Study

NCT00386126

Heart Failure Anemia

UNKNOWN PHASE2/PHASE3

Short Term Oral Iron Supplementation in Systolic Heart Failure Patients Suffering From Iron Deficiency Anemia

NCT02998697

Heart Failure, Systolic Iron-deficiency Anemia

COMPLETED PHASE2/PHASE3

Short-Term Effects & Safety of an Accelerated Intravenous Iron Regimen in Patients With Heart Failure

NCT01925703

Heart Failure Iron Deficiency Anemia

COMPLETED PHASE4

Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality

NCT03036462

Systolic Heart Failure Iron Deficiency

COMPLETED PHASE4

Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron Deficiency

NCT02937454

Iron Deficiency Heart Failure

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a placebo-controlled, double-blind and randomized clinical trial that will include patients with symptomatic stable chronic heart failure (New York Heart Association Functional Class II or III), with diagnosis of iron deficiency (ferritin \<100 ng / dL or ferritin between 100 - 300 ng / dL and transferrin saturation \<20%) followed in an outpatient clinic. The enrolled patients (n = 36) will be randomly allocated in the ratio 2:1 to treatment with 60 mg of elemental iron orally (n = 24) or placebo administration (n = 12), 3 times daily for 4 months. The primary outcome investigated will be an increase of the transferrin saturation ≥ 10 percentage points between baseline and after the intervention. Secondary outcomes of the study will be the change in iron stores, red blood cell indices, neurohumoral activation, left ventricular systolic function, functional capacity, mechanoreflex activity, and quality life score.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ferrous sulfate

Group Type EXPERIMENTAL

Ferrous sulfate

Intervention Type DIETARY_SUPPLEMENT

200mg of ferrous sulfate three times a day for 4 months

Placebo

Group Type PLACEBO_COMPARATOR

Placebo starch

Intervention Type DIETARY_SUPPLEMENT

200mg of placebo starch three times a day for 4 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ferrous sulfate

200mg of ferrous sulfate three times a day for 4 months

Intervention Type DIETARY_SUPPLEMENT

Placebo starch

200mg of placebo starch three times a day for 4 months

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Both gender patients aged over 18 years;
* Diagnosis of chronic heart failure (identified by the use of Framingham criteria) for ≥ 6 months;
* New York Heart Association functional class II and III;
* Left ventricular ejection fraction ≤ 45%
* Regular attendance in an outpatient Heart Failure Clinic;
* Adequate therapeutic drug for heart failure syndrome based on beta-adrenergic blocker, angiotensin converting enzyme inhibitor or angiotensin receptor blocker, and mineralocorticoid receptor blocker;
* Evidence of iron deficiency in biochemical analyses: ferritin values \< 100 ng/dL or between 100 ng/dL and 300 ng/dL, with transferrin saturation \< 20%;
* Hemoglobin value between 9,0 - 16 g/dL;
* Provide written informed consent.

Exclusion Criteria

* Recent device implant (in the last 3 months) or perspective of device implantation (conventional or multisite pacing) in the next 6 months;
* Known active infection, inflammatory disease or C-reactive protein \> 20 mg/dL
* Immunosuppressive therapy;
* In use of erythropoietin and/or current treatment with oral or intravenous iron;
* Clinically bleeding or blood transfusion in previous 3 months;
* Renal failure on dialysis;
* Hemoglobinopathies, hemochromatosis or active malignancy;
* Unstable angina pectoris or clinically significant uncorrected valvular disease, except mitral and tricuspid regurgitation secondary to ventricular dilatation;
* Acute myocardial infarction or acute coronary syndrome, transient ischaemic attack within the last 3 months;
* Uncontrolled arterial hypertension;
* Evidence of comorbidity that features active systemic disease, i.e. liver disease, collagen disease and untreated hyperthyroidism or hypothyroidism;
* Pregnant or lactating women;
* Anaemia due to reasons other than iron deﬁciency (i.e. vitamin B12 deficiency);
* Recent admission for decompensated heart failure (last 3 months).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No